Effect of cessation of highly active antiretroviral therapy during a discordant response: Implications for scheduled therapeutic interruptions

被引:9
作者
Hawley-Foss, N
Mbisa, G
Lum, JJ
Pilon, AA
Angel, JB
Garber, G
Badley, AD
机构
[1] Ottawa Hosp, Div Infect Dis, Res Inst, Ottawa, ON K1H 8L6, Canada
[2] Univ Ottawa, Ottawa Hosp, Res Inst, Ottawa, ON, Canada
基金
英国医学研究理事会;
关键词
D O I
10.1086/321902
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Although treatment with combination antiretroviral therapy leads to a reduction in the level of plasma viremia and an improvement in CD4 T cell count for most patients, for a minority of patients, an improvement in CD4 T cell count occurs despite the failure of treatment to suppress viral replication. Recent reports suggest that these discordant improvements in CD4 T cell count may last for months to years and are associated with improved clinical outcomes. In a retrospective observational study, we evaluated the effect of therapy cessation on 8 patients with discordant immunologic responses to therapy and found that improved CD4 T cell responses are dependent upon ongoing drug pressure. If antiretroviral agents that are likely to resuppress the virus are not available, we suggest that patients continue the therapy associated with immunologic improvement to maximize the clinical benefit of the discordant response.
引用
收藏
页码:344 / 348
页数:5
相关论文
共 37 条
[31]   Decreased HIV-associated T cell apoptosis by HIV protease inhibitors [J].
Phenix, BN ;
Angel, JB ;
Mandy, F ;
Kravcik, S ;
Parato, K ;
Chambers, KA ;
Gallicano, K ;
Hawley-Foss, N ;
Cassol, S ;
Cameron, DW ;
Badley, AD .
AIDS RESEARCH AND HUMAN RETROVIRUSES, 2000, 16 (06) :559-567
[32]   Effect of the human immunodeficiency virus epidemic on mortality from opportunistic infections in the United States in 1993 [J].
Selik, RM ;
Karon, JM ;
Ward, JW .
JOURNAL OF INFECTIOUS DISEASES, 1997, 176 (03) :632-636
[33]   Human immunodeficiency virus type 1 protease inhibitor modulates activation of peripheral blood CD4+ T cells and decreases their susceptibility to apoptosis in vitro and in vivo [J].
Sloand, EM ;
Kumar, PN ;
Kim, S ;
Chaudhuri, A ;
Weichold, FF ;
Young, NS .
BLOOD, 1999, 94 (03) :1021-1027
[34]  
TELENTI A, 1998, ANTIVIR THER S, V3, P53
[35]  
Weichold FF, 1999, J HUMAN VIROL, V2, P261
[36]   Outcome and predictors of failure of highly active antiretroviral therapy: One-year follow-up of a cohort of human immunodeficiency virus type 1 infected persons [J].
Wit, FWNM ;
van Leeuwen, R ;
Weverling, GJ ;
Jurriaans, S ;
Nauta, K ;
Steingrover, R ;
Schuijtemaker, J ;
Eyssen, X ;
Fortuin, D ;
Weeda, M ;
de Wolf, F ;
Reiss, P ;
Danner, SA ;
Lange, JMA .
JOURNAL OF INFECTIOUS DISEASES, 1999, 179 (04) :790-798
[37]   Loss of viral fitness associated with multiple Gag and Gag-Pol processing defects in human immunodeficiency virus type 1 variants selected for resistance to protease inhibitors in vivo [J].
Zennou, V ;
Mammano, F ;
Paulous, S ;
Mathez, D ;
Clavel, F .
JOURNAL OF VIROLOGY, 1998, 72 (04) :3300-3306